International Guideline Harmonization Group
  • Home
  • About IGHG
    • Members
      • Core group
      • Guideline panels
        • Bone mineral density
        • Breast cancer
        • Cardiomyopathy
        • Central nervous system neoplasms
        • Colorectal cancer
        • Coronary artery disease
        • Dexrazoxane cardioprotection
        • Fatigue, mental health and psychosocial problems
        • Fertility preservation
        • Growth hormone treatment
        • Health promotion
        • Hepatic toxicity
        • Hypothalamic-pituitary dysfunction
        • Male gonadotoxicity
        • Metabolic syndrome
        • Nephrotoxicity
        • Neurocognitive problems
        • Obstetric care
        • Ototoxicty
        • Premature ovarian insufficiency
        • Pulmonary dysfunction
        • Splenic dysfunction
        • Thyroid cancer
        • Thyroid dysfunction
        • Anthracycline cardiotoxicity equivalence ratio
        • COVID-19 Statement
    • Collaborators
    • Funding sources
    • Methods
      • Process
      • Grading system
      • Topic selection
      • Publication
      • Handbook
  • Guidelines
    • Topics
      • Bone mineral density
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Breast cancer
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Cardiomyopathy
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Central nervous system neoplasms
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Colorectal cancer
        • Guideline panel
      • Coronary artery disease
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Dexrazoxane cardioprotection
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Fatigue
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Fertility preservation
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publications
        • Guideline panel
      • Growth hormone treatment
        • Guideline panel
      • Health promotion
        • Guideline panel
      • Hepatic toxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Hypothalamic-pituitary dysfunction
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Male gonadotoxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Mental health problems
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Metabolic syndrome
        • Guideline panel
      • Nephrotoxicity
        • Guideline panel
      • Neurocognitive problems
        • Guideline panel
      • Obstetric care
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Ototoxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Premature ovarian insufficiency
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Psychosocial problems
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Pulmonary dysfunction
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Splenic dysfunction
        • Guideline panel
      • Thyroid cancer
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Thyroid dysfunction
        • Guideline panel
      • Anthracycline cardiotoxicity equivalence ratio
        • Guideline panel
      • COVID-19 Statement
  • Patient education
  • News
  • Meetings
  • Contact

Hypothalamic-pituitary dysfunction

Home Guidelines Topics Hypothalamic-pituitary dysfunction Evidence tables

  • Topics
    • Bone mineral density
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Breast cancer
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Cardiomyopathy
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Central nervous system neoplasms
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Colorectal cancer
      • Guideline panel
    • Coronary artery disease
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Dexrazoxane cardioprotection
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Fatigue
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Fertility preservation
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publications
      • Guideline panel
    • Growth hormone treatment
      • Guideline panel
    • Health promotion
      • Guideline panel
    • Hepatic toxicity
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Hypothalamic-pituitary dysfunction
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Male gonadotoxicity
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Mental health problems
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Metabolic syndrome
      • Guideline panel
    • Nephrotoxicity
      • Guideline panel
    • Neurocognitive problems
      • Guideline panel
    • Obstetric care
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Ototoxicity
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Premature ovarian insufficiency
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Psychosocial problems
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Pulmonary dysfunction
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Splenic dysfunction
      • Guideline panel
    • Thyroid cancer
      • Recommendations
      • Conclusions of evidence
      • Evidence tables
      • Publication
      • Guideline panel
    • Thyroid dysfunction
      • Guideline panel
    • Anthracycline cardiotoxicity equivalence ratio
      • Guideline panel
    • COVID-19 Statement

Evidence tables

The evidence tables of hypothalamic-pituitary dysfunction surveillance for childhood, adolescent and young adult cancer survivors are presented in the following document:

Evidence tables hypothalamic-pituitary dysfunction

See Endocrine Reviews for the publication.

  • Contact
  • Disclaimer

© International Guideline Harmonization Group